Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO

• The IPO was increased from 12.5 million shares raising $212.5 million to 17 million shares raising $289 million, indicating strong investor demand for biopharma listings
• Goldman Sachs affiliate will hold approximately 5.7% stake in the company post-IPO
• Proceeds will fund development of lead drug candidates targeting inflammatory skin conditions and inflammatory bowel disease using the company's ATTOBODY platform

Goldman Sachs-Backed Attovia Targets $731.5M Valuation in Upsized IPO

Attovia Therapeutics, a biopharmaceutical company backed by Goldman Sachs, is pursuing a $731.5 million valuation in an expanded initial public offering, indicating robust investor appetite for biopharma listings.

Key Details:

The San Carlos, California-based company increased its IPO size significantly, now seeking to raise $289 million by offering 17 million shares, up from its initial target of $212.5 million through 12.5 million shares. A Goldman Sachs-affiliated entity will retain approximately 5.7% ownership following the offering.

Company Profile:

Founded in 2023, Attovia develops biologic therapies for immune-mediated diseases using its proprietary ATTOBODY platform. The company's pipeline focuses on drug candidates targeting inflammatory skin conditions and inflammatory bowel disease.

Use of Proceeds:

IPO funds, combined with existing cash reserves, will support advancement of lead drug candidates, finance research and development activities, and fund working capital and general corporate operations.

Market Implications:

The upsized offering suggests strong institutional demand for biopharmaceutical investments, particularly in the immunology sector. The company's ability to increase its IPO size by approximately 36% reflects investor confidence in its technology platform and therapeutic pipeline despite being a relatively young company.

Trading Details:

Attovia plans to list on the Nasdaq Global Market under ticker symbol "ATTO." The offering is led by prominent underwriters including Morgan Stanley, Leerink Partners, Citigroup, and RBC Capital Markets, indicating significant Wall Street support for the transaction.

The successful pricing and market reception will serve as a barometer for near-term biopharma IPO activity.